COMET-1 study stays course, Exelixis falls on investor hopes
This article was originally published in Scrip
Exelixis shares took a beating on 26 March based on an interim review of the Phase III COMET-1 clinical trial for Cometriq (cabozantinib) in the treatment of metastatic castrate-resistant prostate cancer (mCPRC), but not because the analysis revealed a specific safety or efficacy concern.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.